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In an influential paper, Kosfeld et al. (2005) showed that intranasal administration of 13 
Oxytocin (OT) increases the transfers made by investors in the trust game – suggesting that 14 
OT increases trust in strangers. While subsequent studies investigating the role of OT in the 15 
trust game found inconclusive effects on the trusting behavior of investors, they deviated 16 
from the Kosfeld et al. study in an important way as they did not implement a minimal social 17 
contact between the investors and the trustees in the trust game. Here, we will carry out a 18 
large double blind and placebo controlled replication study of the effects of OT on trusting 19 
behavior that implements the minimal social contact condition and compares it with a no‐20 
social‐contact condition. The sample generates a power of more than 95% to detect a true 21 
effect of OT on trusting behavior in the trust game. 22 
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All positive human relationships involve trust, making it one of the most widely‐studied topics 23 
in the social sciences. To learn more about the biological basis of trust, researchers have 24 
investigated the potential causal link with the hormone oxytocin (OT), a neuropeptide with a 25 
central role in regulating social approach and attachment behaviors in many non‐human 26 
mammals
1–3
. In humans, OT is mostly known for its functions in childbirth and breastfeeding, 27 
but it can also alleviate social stress, for example, by lowering salivary cortisol levels
4
, increasing 28 
parasympathetic control of the heart
5
, and attenuating amygdala activation in response to 29 
seeing faces
6,7
. It is therefore possible that OT could reduce social apprehension between 30 
strangers and facilitate trust. 31 
This question has sparked more than a decade of research ever since the first report that 32 
administering a single dose of intranasal OT (compared to placebo) increases the willingness to 33 
trust in a dyadic economic game with real monetary stakes
8
. In this game, two anonymous 34 
players are assigned the role of either an investor or a trustee, and both the investor and the 35 
trustee have the same monetary endowment. The investor can transfer money from his 36 
endowment to the trustee, knowing that the transferred amount will be multiplied by a factor 37 
of three. The trustee, who now enjoys a substantial financial advantage, can honor the 38 
investor’s decision with a back transfer, thus sharing the proceeds of the investment. When the 39 
investor entrusts a large amount and the trustee is fair by sending back, say, 50% of the 40 
available amount, both earn a higher income. However, the trustee can also act selfishly and 41 
keep everything for himself, making the investor worse off than if he had not trusted at all. The 42 
highly interdependent nature of this game thus places the burden of uncertainty on the 43 
investor, because the investor does not know how the trustee will respond to his transfers. If 44 
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both players are selfish and know that their partner is selfish the investor will transfer nothing 45 
because he or she knows that the trustee will maximize self‐interest and return nothing. This 46 
solution is, however, suboptimal because it reduces the payoffs for both the investor and the 47 
trustee relative to what they could have earned if the investor trusts fully and the trustee 48 
behaves trustworthily.  49 
Money transfers in the trust game indicate that investors are willing to tolerate a certain 50 
level of uncertainty. Interestingly, the worry that another person may not reciprocate appears 51 
to influence transfers beyond the perceived riskiness of the game
9,10
, i.e., it is not just the risk of 52 
losing money but the fear of being cheated (i.e., betrayal aversion) that inhibits the investors’ 53 
trust. Kosfeld et al.
8
 hypothesized that if trust entails overcoming the fear of betrayal in order 54 
to attain a profitable interaction, the psychophysiological mechanisms underlying trusting 55 
decisions might be similar to those underlying social attachment in other mammals and, 56 
therefore, OT might facilitate trusting behavior ‐ a view that is consistent with the results in 57 
Kosfeld et al.
8
  58 
Cited more than 1600 times in the Web of Science (and more than 3500 times in Google 59 
Scholar, as of August 22, 2018), the Kosfeld et al.
8
 study has become a classic reference in both 60 





, and group dynamics
16,17
. However, the mounting popularity 62 
of studying OT in the social sciences is currently associated with waves of criticism, because 63 





. Other critics have pointed out 65 





. More specifically, Nave and colleagues
21
 have raised doubt on the robustness 67 
of the oxytocin‐trust association, pointing out that six studies failed to replicate the initial 68 
findings reported by Kosfeld et al.
8
. These studies were, however, not direct replications, i. e., 69 
they did not use the same methods and procedures as the original study. 70 
To move forward with a research paradigm on the biological basis of trust that includes a 71 
role for OT, it is essential to clarify whether OT increases trust, and if so, to establish the 72 
conditions under which this is the case. Because animal research has documented that OT is 73 
primarily a social bonding hormone that activates socio‐emotional neural pathways in the 74 
brain
22,23
, we would also expect the effect of OT in humans to be limited to social situations 75 
where initiating or establishing partnership is important to realize synergy. The Kosfeld et al. 76 
study
8 
already suggested this: OT increased trusting decisions in the trust game, but did not 77 
augment risk‐taking in an identically framed risk game played against a computer. To enhance 78 
the saliency of the social context, participants in the trust game had some minimal social (face‐79 
to‐face) contact with each other in groups prior to playing the game against someone whose 80 
exact identity would not be revealed. Importantly, the social contact had to be minimal to avoid 81 
elevating trust to a level beyond which no further increase could reasonably be expected after 82 
OT administration. The following two conditions thus needed to be fulfilled: (i) the social 83 
contact took place before participants knew they would play the trust game so that they could 84 
not communicate about it, as communication is known to substantially increase cooperation in 85 
social dilemma games (such as the trust game)
24
. (ii) Social contact was not intense enough to 86 
cause strong feelings of social familiarity, as this might also generate a ceiling effect in trust. 87 
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Despite the enormous resonance of the Kosfeld
8
 et al. study, the minimal social contact 88 
feature of the study has often been overlooked or neglected. In fact, replication studies so far 89 
neglected several key features of the trust game played in Kosfeld et al.
8
 Of the six studies that 90 
entered the meta‐analysis in Nave et al.21 – in addition to the Kosfeld8 et al. study – four studies 91 
had fictional partners
25‐28
, one was completely devoid of human contact with other 92 
participants
29
, and participants’ previous experience in a dictator game was likely to confound 93 
the decision to trust in the sixth study
30
. In this last case, the investor was matched with a 94 
partner whom he had been enticed to treat unfairly in an immediately preceding dictator game, 95 
which probably altered the investors’ beliefs about this partner's trustworthiness. Thus each of 96 
the six additional studies in Nave et al.
21
 had one or more problematic features.  97 
The importance of establishing some minimal social contact with real partners was 98 
corroborated in a large (N = 254) behavioral study
31
 in which participants, who did not know 99 
each other’s identity, needed to trust each other to jointly solve a coordination game. In this 100 
two‐person simultaneous move game, participants had the choice of playing a safe strategy 101 
which ensured a low positive payoff without any (social) risk, but they also could achieve a high, 102 
mutually advantageous, payoff if they played the alternative strategy and the partner matched 103 
their choice. However, if the partner did not match their choice of the alternative strategy the 104 
participants earned much less than what they would have earned under the safe strategy. Thus, 105 
the alternative strategy was risky and the players’ had to trust that the partner matched their 106 
risky choice when playing the alternative strategy.  107 
It turned out that intranasal OT significantly increased coordination on the mutually 108 
beneficial alternative strategy, but only if participants first had the opportunity to introduce 109 
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themselves to the whole group of participants from which one was randomly drawn to become 110 
the partner. Without this prior contact, OT significantly reduced coordination on the alternative 111 
strategy.
31
 Since the publication of this study, increasing evidence suggests that OT’s function is 112 
not always consistent with facilitating social approach, but that administering intranasal OT can 113 
also lead to parochial, competitive, and envious behaviors and behaviors that appear to be 114 
driven by schadenfreude
16,17,32
, which have an anti‐social dimension. This points to the need of 115 
examining the conditions under which – and how – OT modulates social behavior
33,34
. 116 
A current leading theory to account for why OT can stimulate both prosocial and anti‐social 117 
behaviors rests on neurological evidence that OT modulates mesolimbic dopaminergic neurons, 118 
thereby affecting both incentive motivation as well as attention re‐orienting. By boosting the 119 
dopaminergic signal in the mesolimbic network, OT is thought to enhance the salience of social 120 
cues that emphasize the value of approach behavior
7,35,36
. Framing the effects of OT in terms of 121 
assigning salience to social cues highlights the importance of establishing minimal social contact 122 
prior to engaging in an interdependent exchange. We propose that minimal social contact is the 123 
cue that enhances the prosocial approach potential of OT and reduces social apprehension, 124 
thereby enhancing trust in an environment where approach behavior is a precondition for a 125 
mutually advantageous exchange. 126 
The purpose of the proposed study is therefore twofold. First, we want to resolve the 127 
conflict regarding the impact of intranasal OT on trusting decisions by conducting a controlled 128 




with sufficient statistical power. Second, we 129 
will investigate the importance of providing social cues by differentiating between a minimal 130 
social contact and a no contact environment. Both conditions involve real and anonymous 131 
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partners, but differ in the degree to which it is possible to establish minimal social contact: in 132 
the minimal contact condition the matched players in the trust game will know that they saw 133 
each other while waiting together with several others in a common room (following similar 134 
procedures as in Kosfeld et al.
8
), while in the no contact condition the players do not meet and 135 
hence have no concrete social cue to relate to each other. To summarize, we propose a 2x2 136 
experimental design with OT versus placebo as the main factors in the first dimension and “no 137 
contact” versus “minimal social contact” being the main factors in the second. The primary 138 
hypotheses are that OT increases trust in the minimal social contact condition, and that this 139 
effect of OT on trust is more pronounced than in the no contact condition. Thus, the proposed 140 
design enables us to examine the role of OT for investors’ trusting behavior in the trust game 141 
and the extent to which this measure of trust is jointly affected by OT and minimal social 142 
contact. We believe that these questions are of primary importance for the field of OT research 143 
but, naturally, our design does not allow us to make broad conclusions about the general 144 
effects of OT on social cognition, empathy or behavior in other experimental paradigms.  145 
 146 
Methods 147 
Study sample and determination of sample size 148 
We will conduct the study in two different locations: in Antwerp, Belgium (n = 352) and in 149 
Magdeburg, Germany (n = 352) with a total of 704 student participants between 18 and 25 150 
years old. According to the a priori power analysis presented in detail below and the robustness 151 
check reported in Supplementary Information 1 and 2, a sample size of n = 704  will provide a 152 
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statistical power of more than 95% for all main hypotheses and also exceeds the sample size 153 
recommendations of Nave et al.
21
. 154 
The sample size for this study is determined based on a series of power analyses in G*Power 155 
3.1.9.2 28 and the effects reported in Kosfeld et al.
8
. This paper reported three effects: 156 
(i) Comparing a placebo and an OT group in a trust experiment with minimal social contact 157 
corresponded to an effect size d = 0.514 (r = 0.249 in a common effect size language). 158 
(ii) They compared the OT group in the trust experiment to the OT group in a risk 159 
experiment in which they hypothesized OT would not exert an influence. This yielded an effect 160 
size of d = 0.701 (r = 0.331), which corresponds to an intermediate effect
37
.  161 
(iii) To bolster their results, Kosfeld et al.8 assessed the global difference between all four 162 
experimental groups under consideration (trust/Placebo, trust/OT, risk/Placebo, and risk/OT) to 163 




 were forced to use non‐parametric tests in their study because their sample 166 
did not comply with assumptions made in parametric tests. Specifically, the smallest sample 167 
size in testing (i)‐(iii) was n=29. They thus applied Mann‐Whitney‐U tests in (i) and (ii), but 168 
implemented Kruskal‐Wallis‐H for comparison (iii). Our study will overcome these drawbacks 169 
because we will recruit a large sample that will enable us to use OLS regression techniques. 170 
Given our 2x2 experimental design, the test that would corresponds to (i) compares trust in the 171 
minimal social contact condition between the OT and the Placebo group. The test most similar 172 
to (ii) compares trust under OT between the no‐contact and the minimal social contact 173 
condition, and a test similar to (iii) examines whether the trust levels in the four conditions 174 
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differ from each other. Note, however, that the tests described in (ii) and (iii) in the Kosfeld 175 
study
8
 are about comparisons between a trust and a risk game, which differ substantially from 176 
the current design which does not have a risk game (i.e., a game played against a computer). 177 
Our second factor (minimal social contact versus no contact) establishes variation within a trust 178 
game played with real partners.  179 
We base our a priori power analysis on the effect size d = 0.514, reported in test (i) of 180 
Kosfeld et al.
8
 and the requirement of a one‐tailed test, which is justified when testing a 181 
directional
38
 hypothesis. The power analysis shows that with α = .05, β = .95, and a one‐tailed t‐182 
test we must recruit 166 observation units to detect a significant difference of OT in the 183 
minimal contact condition of the proposed experiment (i.e., replicating effect (i), see 184 
Supplementary Table 1). Since the proposed experiment will also include a no contact 185 
condition, the total necessary sample size is 166×2 = 332. Because we plan to have 16 186 
participants per session with 22 sessions we will have n = 352 participants per location, which 187 
gives us in total n = 704 observations. Based on the reported effect size in result (i) of Kosfeld et 188 
al.
8
, the overall sample size of n = 704 will provide a statistical power of 99.65%.  189 
However, because of publication bias and other reasons the first results of a study design 190 
such as Kosfeld et al.
8 
may overstate the true effect size, we conduct a further robustness check 191 
in our a priori power analysis by applying Simonsohn’s “small telescopes” approach for 192 
replication studies
39
. Instead of pondering whether or not it is adequate to assume an effect 193 
size of 0.514, the small telescopes approach assesses whether the replication is sufficiently 194 
powered so that it is able to detect an effect reported in an original study that may have been 195 
“small” or “underpowered”. In addition, it differentiates noisy replication effects (yielding p > 196 
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.05) from those that genuinely indicate the effect is undetectably different from zero. 197 
Specifically, the small telescopes method first ask what effect size d* would give the original 198 
study 33% statistical power. Then, in a second step, one computes the number of observations 199 
that is necessary to achieve 80% power to detect the relatively small effect size d* in the 200 
replication study. According to this method, already an overall sample size of n = 488 yields an 201 
adequate replication of the Kosfeld study
8
 (see Supplementary Table 2). 202 
 203 
Exclusion criteria 204 
We limit recruitment to male participants for several reasons. First, the main motivation for the 205 
study is to replicate the Kosfeld et al.
8
 study, which was conducted only with males. Second, we 206 
know from the previous literature that sex‐specific gonadal steroids influence OT‐receptor 207 
binding in the brain, and that intranasal oxytocin can affect the behavior of males and females 208 
differently, even in opposite directions
40
. Such inter‐individual differences might introduce 209 
excessive noise in the data which could obscure the results. Third, for practical reasons (given 210 
that oxytocin induces labor), we wanted to avoid having to administer pregnancy tests to all 211 
female participants, which would be required by Ethics Commissions. Finally, in pilot studies 212 
(see Supplementary Table 3a) conducted to develop an appropriate minimal social contact 213 
condition that avoids ceiling effects, we noted that the gender composition of the social group 214 
had a significant impact on subsequent trusting behavior (Supplementary Table 3b). 215 
Other exclusion criteria for participation include (1) psychiatric disorders that may impact 216 
the expected effects of OT in healthy populations, and (2) somatic conditions that may impact 217 
effective absorption of intranasal OT. To identify psychiatric symptoms, online registration will 218 
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include a questionnaire with the following items: (a) Have you ever been diagnosed with a 219 
psychiatric disorder? (b) Have you experienced recurrent problems with substance abuse? (c) 220 
Are you currently or have you in the past been seeing a psychiatrist, psychologist, or 221 
psychotherapist? (d) Do you currently or have you in the past taken psychoactive medication, 222 
i.e., sleep medication, anxiety medication, antipsychotics, or antidepressants? If the answer is 223 
“yes” to any of these questions, the participant will be contacted by a certified psychologist 224 
who will conduct a structured interview to determine if the condition meets diagnostic criteria 225 
for psychiatric disorders in DSM‐IV. Based on the psychologist’s diagnostic report we will 226 
consider the following disorders as exclusion criteria for the current study: psychotic disorders 227 
or mood disorders with psychotic features; major depressive or (hypo)manic episode; 228 
generalized anxiety disorder; panic disorder; agoraphobia or social phobia; obsessive 229 
compulsive disorder; alcohol abuse and dependence, and non‐alcoholic psycho‐active 230 
substance use disorder. 231 
To identify somatic conditions, we query participant’s history of nasal diseases by (i) asking if 232 
participants ever had surgery on the nose and (ii) by administering a standardized and validated 233 
questionnaire for subjective assessment of nasal obstruction (NOSE)
41,42
. Participants who have 234 
had surgery on the nose or who score in the “severe” range on the NOSE questionnaire
41
 are 235 
excluded from further data analysis. 236 
Via a post experimental questionnaire, we identify two post hoc exclusion criteria: (1) 237 
suffering from a common cold or allergic rhinitis on the day of the experiment, which will be 238 
assessed subjectively using the standardized Visual Analogue Scale (VAS). The VAS comprises a 239 
10 point scale whereby the extreme cases are given by “nose feels extremely clear,” (= 0) and 240 
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“nose feels extremely blocked.” (= 10). The score on this scale has been shown to correlate 241 
specifically with inspiratory flow in the upper nasal cavity
43,44
. Participants who have a score ≥ 8 242 
on the VAS are considered to have severe nasal obstruction
43
 and will be removed from the 243 
data before analyses. We also assess (2) compliance with the online registration instructions to 244 
abstain for at least 12 hours from alcohol, non‐prescription drugs, and heavy smoking (>20 245 
cigarettes) prior to attending the experiment. Because of the anti‐diuretic properties of OT, we 246 
ask participants to restrict their general consumption of liquids (e.g. water) two hours prior to 247 
the experiment to prevent an inadvertent increase of the possibility of water intoxication. 248 
Participants who indicate on the day of the experiment that they drank more than one liter in 249 
the hour preceding the experiment will not be allowed to self‐administer the spray and will no 250 
longer be included in the dataset. We will also exclude participants from the dataset based on 251 
their answer to specific questions regarding tobacco‐, alcohol‐ and drug use. We will exclude 252 
the data of participants who smoked > 20 cigarettes or drank any alcohol on the day of the 253 
experiment, and of participants who used non‐prescription (recreational) drugs on the day or 254 
the night before the experiment. We deliberately collect information about these behaviors 255 
immediately after the experiment (i.e., after participants have been paid) so that they have no 256 
incentive to lie. 257 
A final criterion is participants’ understanding of the trust game instructions. We will check 258 
this by letting them compute the monetary payoffs for both players in two hypothetical 259 
examples of the trust game. Both examples need to be solved correctly to be included in the 260 
data analyses.  261 
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Participants will be recruited by e‐mail and announcements posted on the university’s 262 
electronic learning platform (Antwerp), or via an existing participant pool platform 263 
(Magdeburg) that introduces the study as “The psychobiological foundations of decision‐264 
making”. Participation will be voluntary, and all participants will sign an informed consent form. 265 
The proposed study will be carried out with the approval of the Medical Ethics Commissions of 266 
the Universities of Antwerp and Magdeburg. 267 
 268 
Study design 269 
We will test the combined effects of OT and minimal social contact on trust in a 2 × 2 factorial 270 
design (OT/placebo x minimal social contact/no contact), where each treatment is a between 271 
factor. Participants’ level of trust (the dependent variable) will be assessed with a single 272 
decision in a dyadic incentivized trust game (similar to Berg and colleagues
45
). Trust is measured 273 
by how many euros participants in the role of the investor are willing to transfer to another 274 
participant, the trustee. Measuring trust with a single decision (rather than averaging several 275 
consecutive decisions) has the advantage that it prevents hedge betting and may thus 276 
encourage intuitive thinking, which is the decision making type OT is most likely to influence,
7,47
 277 
rather than complicated deliberation. 278 
The trust game is programmed in z‐tree 47, and played on computers linked in a local 279 
network. The script will be made accessible via the Open Science Framework. Each person in a 280 
dyad is assigned the role of an investor or a trustee. As in Kosfeld et al.
8
, both the investor and 281 
the trustee receive an initial endowment of 12 euros, and the investor can decide to send 0, 4, 282 
8, or 12 euros to the trustee. The experimenter triples each euro the investor transfers, and this 283 
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amount is added to the initial 12 euro endowment of the trustee. Then the trustee has the 284 
option of sending back any amount between zero and the total amount available to him. The 285 
experimenter does not triple the back transfer. The investor’s payoff corresponds to the initial 286 
endowment minus the transfer to the trustee, plus the back transfer from the trustee. The 287 
trustee’s payoff is given by his initial endowment plus the tripled transfer of the investor, minus 288 
the back transfer to the investor. 289 
Each participant will play this game twice, with two different partners: first as an investor, 290 
and then as a trustee. This ensures that for every investment decision there is also a trustee 291 
who decides on a back transfer. The first game in the role of the investor occurs without 292 
knowing that there will be a second game in the role of a trustee, and no feedback will be given 293 
in between games. In both roles, participants play the trust game for real money. 294 
Participants will be randomly assigned to one of the four treatment conditions (no 295 
contact/Placebo, no contact/OT, minimal social contact/Placebo, minimal social contact/OT) 296 
but randomization will be stratified based on participants’ social value orientation (SVO) which 297 
will be measured during registration two weeks prior to the experiment with an online survey. 298 
This stratification ensures that the distribution of individuals’ SVOs will be the same in each 299 
treatment condition. SVO is a relatively stable personality feature describing a person’s intrinsic 300 
willingness to behave prosocially
48
, that has been found to predict trusting decisions
49
 and 301 
sensitivity to social cues
50
. OT/placebo administration will be double blind following a 302 




Spray administration 305 
A recent study investigating the dose dependency of oxytocin reports that a dose of 24 IU OT is 306 
more effective in triggering an amygdala response and eliciting fear reduction compared to 307 
either lower (12 IU) or higher (48 IU) doses
51
, although this contradicts an earlier study in which 308 
8 IU was found to be the most effective
52
. The latter study, however, made use of a Breath 309 
Powered device for OT administration which is likely to have increased absorption significantly. 310 
Because the aim of the study is to replicate the Kosfeld et al.
8 
study as close as possible, we will 311 
have participants self‐administer 24 IU OT or a placebo by means of a metered finger sprayer 312 
(see Supplementary Figure 1). The solutions, containing 1 ml of either syntocinon (Novartis) or 313 
an isotonic solution with no active ingredient, are prepared by the pharmacy of the University 314 
Hospital pharmacy.  315 
As accumulating evidence suggests that the most likely uptake of intranasal OT into the brain 316 
occurs directly via the olfactory or trigeminal nerve (rather than via the circulatory system)
53
, 317 
participants will receive detailed written and oral instructions (following the guidelines of 318 
Guastella et al.
54
, see Supplementary Table 4) to make sure that the spray reaches the posterior 319 
upper end of the nasal cavity where absorption can take place.  All experimenters will train 320 
themselves to use the spray bottles properly. During the experimental session we will have a 321 
ratio of one supervisor for 4 participants. The supervisor will take notes on any problems 322 
participants may be experiencing with the spray and rate whether they properly self‐323 
administered the spray on a 5 point likert scale. If participants are rated as non‐compliant with 324 
the rules for self‐administration (category 5) or the self‐administration is judged as problematic 325 
by the supervisor (category 4) the participant is ruled out from data analysis. Participants 326 
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themselves will also report on a 5 point likert scale the discomfort they experienced (if any) 327 
from the spray. Scores on this scale will not serve as exclusion criteria, but will be used in 328 
further exploratory analyses to assess if nasal spray discomfort might interfere with proper OT 329 
administration and affect the behavioral results. 330 
 331 
Experimental procedures  332 
Participant recruitment will start at least two weeks prior to the experiment. Registration 333 
occurs online and includes filling out the triple dominance measure for social value orientation 334 
(SVO)
48;
 the inclusive generalized trust scale
49
, a measure of risk attitude
55
, and two 335 
questionnaires assessing attitudes towards social contact (the shortened version of the Autism 336 
Spectrum Questionnaire (ATQ10)
56
 and the sociability dimension of the HEXACO scale
57
. The 337 
trust and risk measures will serve as control variables when testing the primary (a priori) 338 
hypotheses (described in the next section), while the other variables will serve as moderators in 339 
further exploratory analyses.  340 
On the day of the experiment, participants will arrive at the agreed upon time and meeting 341 
point. They will be escorted individually to a cubicle in the computer room, at which point they 342 
will be asked to sign the informed consent. They will not talk to anyone (except to the room 343 
supervisor, if necessary). To guarantee anonymity, their names will from then on be replaced by 344 
a self‐made, retrievable code through which they can be identified during the remainder of the 345 
study.  346 
Participants begin by filling out a 30‐item multidimensional mood state (MDMS) 347 
questionnaire
58
 and subsequently receive guidelines for spray administration. Participants will 348 
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then self‐administer three puffs of the nasal spray in each nostril, and, following the procedures 349 
of Kosfeld et al.
8
, wait 50 minutes before continuing with decision‐making in the trust game. 350 
During this waiting period the procedures for the no‐contact and the minimal social contact 351 
condition will differ (see Figure 1). 352 
353 
Figure 1. Condensed overview showing the main difference between the no‐contact condition and the 354 
minimal social contact condition. The top arrow represents the time (in minutes) elapsed. The light 355 
grey boxes below describe the procedures, while the dotted‐line boxes indicate where the experiment 356 
is taking place. The two experimental conditions differ only during the 50 minute waiting period.  The 357 
questionnaires (indicated by *) are described in the text. 358 
 359 
In the no‐contact condition, participants will remain seated in their cubicles for the entire 360 
waiting period, and will fill out questionnaires that enable us to measure their negative 361 
reciprocity (Global Preferences Scale
55
), personality (the HEXACO‐100 personality inventory57), 362 
fluid intelligence (Raven matrices task), and their level of arousal
59,60
. They will also fill out the 363 
MDMS questionnaire for a second time. This will enable us to check for mood changes 364 
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following nasal spray administration. During the last minutes of the waiting period, they will 365 
familiarize themselves with the trust game instructions. 366 
In the minimal social contact condition, participants fill out the same questionnaires as in the 367 
no‐contact condition. However, after 30 minutes into the waiting period, they will move 368 
together to a common room, where they will be seated at a communal table. They will be told 369 
that they have to sit here for roughly 8 minutes during which they fill out the MDMS and 370 
arousal questionnaires. They are told that they can talk quietly to each other, but they are not 371 
explicitly encouraged to do so. When they are done they will be guided back (as a group) to 372 
their respective cubicles, where they will receive the trust game instructions. From that 373 
moment on, the remainder of the experiment proceeds in the exact same way as in the no‐374 
contact condition.  375 
The written instructions for the trust game will vary slightly between the no‐contact and the 376 
minimal contact condition. In the no‐contact condition, participants will read: “During the 377 
study, you will be randomly matched with a participant from another room. Neither before, nor 378 
after the study will you learn the identity of the other participant. In the same way, the other 379 
participant will not be informed about your identity.” In the minimal social contact condition, 380 
participants will read: “During the study, you will be randomly matched with one of the 381 
participants from the other room whom you just met. Neither before, nor after the study will 382 
you learn the exact identity of the other participant. In the same way, the other participant will 383 
not be informed about your identity.” 384 
After concluding the experiment, participants will answer a post‐experimental 385 
questionnaire. Importantly, this questionnaire will query participants’ beliefs regarding the 386 
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treatment they received (OT versus placebo) which allows us to test the possibility of a placebo‐387 
effect. Finally, a number of questions assess participants’ feelings of connectedness with 388 
others, which can be used to test if the minimal social contact and no contact condition differed 389 
in this respect.  390 
Participants are remunerated for their participation. They receive the earnings from the 391 
decisions they made as described in the experimental instructions, plus a 5 euro compensation 392 
for filling in the questionnaires.  393 
 394 
 395 
Data analysis 396 
Hypothesis testing 397 
The dependent variable will be the investor's trust level in the various treatment conditions. 398 
The main explanatory variables are the treatment conditions. We pool the data obtained in 399 
Magdeburg and Antwerp because there is no a priori reason to expect that OT would affect 400 
individuals from these two locations differently. In addition, pilot studies conducted during the 401 
time span December 2017‐March 2018 revealed very similar trusting behaviors between the 402 
two locations (Supplementary Table 3a and Supplementary Figure 2). But to be on the safe side 403 
we will still control for generalized trust
49
 and general risk attitude
55 
in our regressions. Adding 404 
these two covariates will also reduce the standard errors in our treatment estimates – thus 405 
allowing sharper estimates – and correct for potential imbalances in the samples that occur 406 
through imperfect randomization. We do not plan to include social value orientation
48
 as a 407 
covariate because we control for SVO via stratified randomization. We will run the following 408 
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OLS‐regression where T = Trust; OT = Oxytocin treatment; MSC = minimal social contact 409 
condition; NoC = no contact condition):		 410 
= +	 +	 +	 × 	 + 	 	 , 	  
In this regression, the Placebo/NoC treatment is the omitted category and β0 measures the 411 
trust level in this treatment. Neglecting the covariates, the average trust levels in the four 412 
treatments are given by the matrix in Table 1: 413 
 414 
 Placebo (P) Oxytocin (OT) 
No Contact (NoC)  +	  
  Minimal Social Contact (MSC) +  +	 	+		 +	  
Table 1. Regression coefficients estimating trust in each of the four experimental conditions 415 
 416 
We test the following a priori hypotheses regarding the effect of OT and express them also in 417 
terms of the coefficients of the above regression model: 418 
H1: OT has a positive influence on trust in the MSC condition, i.e., β1 + β3 > 0. This is the 419 
replication of the Kosfeld et al.
8
 study, as delineated in finding (i) in the section on the 420 
determination of the sample size. 421 
H2: The influence of OT on trust in the MSC condition (which is given by β1 + β3), is higher than 422 
the influence of OT on trust in the NoC condition (which is given by β1), that is, β3 > 0. 423 
In addition we formulate a third hypothesis about the influence of the MSC condition:  424 
H3: In the placebo treatment, Trust is higher in the MSC condition than the NoC condition, i.e., 425 
β2 > 0. 426 
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As we do not have a priori expectations about the effect of OT in the NoC condition (i.e., 427 
whether β1>0), we do not formulate a hypothesis. Similarly, although our design enables us to 428 
check whether the influence of MSC on trust levels in the OT treatment (which concerns β2 + 429 
β3) will be significantly different from zero, we consider this of secondary interest for the 430 
present study.  431 
If the analysis yields a non‐significant p‐value, Bayesian hypothesis testing will be used to 432 
assess the relative evidence for the different hypothesis.
61
 For example, a Bayesian analysis of 433 
H1 (β1 + β3 > 0) above computes whether the likelihood (L) of a model that captures the 434 
potential effect of OT (β1) and the interaction effect between OT and MSC (β3) is sufficiently 435 
more likely, given the data, than a model that assumes that both β1 and β3 are zero.  436 
We will use the “regression BF” function in the Bayes Factor R package, using a JZS/Cauchy 437 
prior with a scaling constant of r=0.354, which corresponds to a prior with a medium width. We 438 
will also conduct robustness checks using larger values (r=0.5 and r=0.707) corresponding to 439 
wider and flatter prior distributions. For each hypothesis we test, we will compute a Bayes 440 
factor which provides an indication of how much more likely the hypothesized model is than 441 
the null model (i.e., no effect of Oxytocin on trust). We will consider a Bayes factor of 10 as 442 
sufficient evidence for the hypothesized model over the null model, a value that is considered 443 





The anonymized dataset generated and analyzed during the current study will be shared 445 
publicly.  446 
 447 
  448 
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Supplementary Table 1. A priori sample size computation using the G*Power 3.1.9.2 28 6 
software
1  
  7 
 8 
t-tests: Difference between two independent means (two groups) 
Analysis A priori: compute required sample size 
Input Tail(s) One 
 Effect size d 0.514 
 α error prob 0.05 
 Power (1-β error prob)  0.95 
 Allocation ration N2/N1 1 
Output Noncentrality parameter δ 3.311 
 Critical t 1.654 
 DF 164 
 Sample size group 1 83 
 Sample size group 2 83 
 Total sample size 166 





  13 
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Supplementary Table 2. Simonsohn’s small telescopes approach
2
 to assess the adequacy of the 14 
sample size of a replication study. This method assesses whether the replication study has 80% 15 
power to detect an effect size the original study had 33% power to detect.   16 
 17 
 18 
t-tests:  Difference between two independent means (two groups) 
Analysis – Step 1 Compute required effect size for the Kosfeld et al.
3
 study with 
33 % power 
Input Tail(s) One 
 α error prob 0.05 
 Power (1-β error prob) 0.33 
 Sample size group 1 29 
 Sample size group 2 29 
Output Noncentrality parameter δ 1.220 
 Critical t 1.672 
 DF 56 
 Effect size d 0.320 
Analysis – Step 2 Compute required sample size using d = 0.32 
Input Tail(s) One 
 Effect size d 0.320 
 α error prob 0.05 
 Power (1-β error prob) 0.80 
 Allocation ration N2/N1 1 
Output Noncentrality parameter 2.502 
 Critical t 1.651 
 Sample size group 1 122 
 Sample size group 2 122 
 Total sample size 244 
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Supplementary Table 3. Mean Investments in the Trust game across 11 pilot sessions 25 
 26 
Supplementary Table 3 documents our effort to develop an experimental design that implements a trust 27 
game with and without a minimal social contact condition but which avoids introducing a ceiling effect for a 28 
potential impact of OT. For example, in experimental sessions 2, 5 and 7 below (which implemented the 29 
Social 1 condition or the Social 1* condition, for a detailed explanation of these conditions see text after 30 
Table S3) the average behavioral trust level was 8.875, 10.875 and 9.437, respectively. These trust levels 31 
are very high and leave little space for OT to have an effect in these conditions. Therefore, we conducted 32 
further pilots with a Social 2 and a Social 3 condition ( see pilot sessions 9 – 11) which tried to mitigate 33 
these potential ceiling effects while still allowing for minimal social contact among the subjects.  34 
 35 








Antwerp 14 No contact 1pt = 
33 c 
5 € mixed all integers 




Antwerp 16 Social 1 1pt = 
33 c 
5 € mixed all integers 




Magdeburg 16 No contact 1pt = 
1€ 
5 € mixed all integers 




Magdeburg 16 No contact 1pt = 
33 c 
5 € mixed all integers 




Magdeburg 16 Social 1* 1pt = 
33 c 
5 € mixed* all integers 




Magdeburg 16 No contact 1pt = 
1€ 
none mixed all integers 




Magdeburg 16 Social 1 1pt = 
1€ 





Magdeburg 16 No contact 1pt = 
1€ 
none males 0, 4, 8, 12 8.250 
9 3-Mar 
2018 
Magdeburg 16 Social 2 1pt = 
1€ 
none males 0, 4, 8, 12 7.500 
10 16 Mar 
2018 
Magdeburg 16 Social 3 1pt = 
1€ 
none males all integers 
(0 – 12) 
8.100 
11 16 Mar 
2018 
Magdeburg 16 Social 3 1pt = 
1€ 
none males 0, 4, 8, 12 8.000 
The social conditions are defined as follows. In Social 1, after being seated and having signed the informed 36 
consent form in the experimental room, eight participants were called to meet each other briefly (5 37 
minutes) in a smaller room (different from the experimental room where the trust game would be played). 38 
They were seated at the same table and then asked to formally introduce themselves by name, mention 39 
their hobby, and shake hands with each other, following the Prior Contact condition described in Declerck 40 
et al. (2010)
3
. In Social 1* (pilot session 5), the experimental rooms were separated by gender (i.e., men 41 
and women were not seated in the same room when they arrived or when they were performing the trust 42 
game). During the social contact moment, four males from one room met four females from another room 43 
and introduced themselves following the same procedures as in Social 1. This led to very high trust levels. In 44 
Social 2 (pilot session 9), eight male participants met in the smaller room without introducing themselves. 45 
They were seated at the same table and waited together for 5 minutes during which they did not speak 46 
4 
 
with each other. This complete lack of verbal interaction caused a strange and akward situation that was 47 
associated with reduced investments. In Social 3 (pilot session 10 and 11), we combined the procedures of 48 
Declerck et al (2010)
3
 and Kosfeld et al. (2005)
4
: eight male participants, coming from 2 separate 49 
experimental rooms where the trust game was to be played, met in a smaller room. They were not asked to 50 
formally introduce themselves, but were told that they were permitted to talk, should they wish to do so. 51 
During the 8 minutes that they waited together, they were sitting at the same table and filled out 52 
questionnaires (see main text). These procedures were examined once with a “continuous” action space for 53 
the investor (i.e., investments from 0 – 12 were possible; in session 10) and once with a restricted 54 
investment space (only investments 0, 4, 8 and 12 were possible; session 11). Pilot session 8, which 55 
implements the no-contact condition, otherwise matches the procedures of session 11.  56 
There were also the following procedural differences between the various pilot sessions. In session 1 57 
and 2 participants sat in computer rooms without cubicles; in all other session, participants sat in 58 
cubicles the entire time, except during the social contact manipulation in the non-experimental 59 
(“smaller”) room. In sessions 1-5 participants arrived at an agreed upon place where they waited 60 
together until the beginning of the experiment. In sessions 6-11, participants were guided immediately 61 
to their cubicles upon arrival. This minimizes the contact with other participants before the experiment 62 
and increases our control over subjects social contacts. The show up fee was removed in sessions 6-11 63 
for the following reason. We hypothesized that if subjects receive a show-up fee of €5 they are more 64 
willing to take social risks in the trust game, i.e., more willing to send their whole endowment of €12 in 65 
the trust game, which exacerbates the ceiling problem discussed above. Instead of giving them a show-66 
up fee of €5 before the trust game we remunerated them ex-post with €5 for filling out questionnaires.  67 
 68 
 69 
Supplementary Table 3b. Mean investments by gender in the mixed gender sessions 1-6 70 
 71 
# Condition Mean all Males Females





























The above table shows that in several of the first 6 sessions there were substantial gender differences in 73 
trust. To avoid this source of variation we decided to conduct the experiment with only male subjects.  74 
 75 
  76 
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Supplementary Table 4. Guidelines for OT administration, based on recommendations by 77 




1 If necessary, clear your nose from any obstruction (box of tissues provided). 
 
2 Prime the bottle and complete a test spray in the air. 
 
3 Sit comfortably and keep the head in an upright position. 
 
4 Close one nostril with one finger while administering the spray to the other nostril. 
 
5 Insert bottle 1 cm into the nostril and keep the tip of the bottle at a 45 degree angle 
into the nose. Aim towards the upper lateral part of the nose (and not towards the 
middle of the nose).  
 
6 Upon delivery, inhale and breathe in lightly. Do not sniff exaggeratedly. 
 
7 Alternate administrations between nostrils. Allow time between each re-
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Supplementary Figure 1. Technical details of finger sprayer used to deliver OT/placebo. Figure 84 







Supplementary Figure 2. Comparison of the distributions of investment decisions in the pilot 90 
studies conducted in Antwerp (N = 14, session 1) and Magdeburg (N = 16, session 4). 91 
Experimental conditions are kept the same: no contact, mixed genders, low stakes ( 1 point = 33 92 
cent) but with a show-up fee. 93 
 94 
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